Previous 10 | Next 10 |
2024-05-23 07:00:00 ET Summary Gilead Sciences has a 4.5% yield. The company has struggled with declining profits and sales in recent years. The company's growth potential lies in its HIV and oncology treatments, but it faces competition and disappointing trial results. Gilead...
– Key Findings from PBC, HDV, HCV, HBV and MASH/Fibrosis Studies Affirm Commitment to Drive Life-changing Science in Liver Disease – Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the ...
NORTHAMPTON, MA / ACCESSWIRE / May 21, 2024 / Driven by our purpose to make the world a healthier place for all people, we've worked to improve health equity and advance equitable access to care. Last week, we brought together leaders, advocates and changemakers to share insights at our inaugura...
2024-05-20 12:37:35 ET More on Gilead Sciences Biopharma M&A surges year over year in Q1 Gilead's Kite, Arcellx share phase 3 trial design for CAR-T multiple myeloma asset Gilead Sciences, Inc. (GILD) RBC Capital Markets Global Healthcare Conference (Transcript) ...
2024-05-19 14:00:55 ET More on pharma companies Novo Nordisk, J&J lead R&D rankings in big pharma: report Shockwave Medical: A Look Into Q1 Financials And Value To Johnson & Johnson Investors Johnson & Johnson: Buy This Bargain Before It's Gone ...
- 70% of Patients Receiving Seladelpar 10mg Achieved the Clinically Meaningful Composite Endpoint and 37% Achieved ALP Normalization at 12 Months - - Reduction in Patient-Reported Pruritus (Itching) was Rapid and Durable in Patients with Moderate to Severe Symptoms - - Pos...
2024-05-16 14:27:26 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Penny stocks to buy understandably offer many enticing attributes, not least of which is the potential for tremendous returns. Of course, the emphasis is on the word “potential. ...
2024-05-15 15:59:09 ET Gilead Sciences, Inc. (GILD) RBC Capital Markets Global Healthcare Conference May 15, 2024 10:30 AM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets ...
2024-05-15 08:45:36 ET Summary Pfizer has been a losing investment for several years, but stronger trading momentum is starting to appear. An easily covered and safety-minded 6% dividend yield is very attractive today. Undervaluation arguments to own shares also exist. PFE sto...
2024-05-14 16:25:24 ET Gilead Sciences, Inc. (GILD) BofA Securities 2024 Health Care Conference May 14, 2024, 02:20 PM ET Company Participants Geoff Meacham - Bank of America Securities Conference Call Participants Andrew Dickinson - Chief Financial Officer ...
News, Short Squeeze, Breakout and More Instantly...
– RADIAN’s Five-Year, $25 Million Extension Will Increase Support for Local Organizations and Drive Progress to Help Turn the Tide on HIV Across the Region – – RADIAN Will Expand Geographic Focus to Provide Key Populations and Communities Im...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Chief Medical Officer Merdad Parsey, MD, PhD, will leave the company early next year. While the company works to identify a successor, Dr. Parsey will continue as Chief Medical Officer until the first quarter of 2025 and support this trans...